2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Matthew A. Lunning, DO, discusses initial treatment considerations in chronic lymphocytic leukemia.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Matthew A. Lunning, DO, assistant professor, Internal Medicine Division of Oncology & Hematology, University of Nebraska Medical Center, discusses initial treatment considerations in chronic lymphocytic leukemia (CLL).
Patients with CLL often present with asymptomatic disease that is identified with a routine complete blood count, Lunning explains.
To confirm a CLL diagnosis, patients typically undergo flow cytometry on peripheral blood, says Lunning. Afterward, a lymphocyte count, hemoglobin count, and platelet count should be conducted.
Additionally, patients should have a physical exam to identify splenomegaly, concerning adenopathy, or irregular lymph nodes, Lunning explains.
Richter’s transformation indicates a poorer prognosis and can significantly alter a patient’s treatment in the newly diagnosed or relapsed/refractory setting, concludes Lunning.
Related Content: